Deepa Prasad - 29 Aug 2023 Form 4 Insider Report for Design Therapeutics, Inc. (DSGN)

Reporting relationship: Director
Issuer ticker: DSGN
Reported as of: 29 Aug 2023
Net transaction value: +$27,670
SEC form: 4
Accepted by SEC: 30 Aug 2023, 18:06:59 UTC
Prior SEC filing: 02 Jun 2023
Next SEC filing: 17 Jun 2024
Source filing: View source filing
Reporting owner signature: /s/ Mustapha Parekh, Attorney-in-Fact

Key filing fact

Deepa Prasad filed Form 4 for Design Therapeutics, Inc. (DSGN) on 30 Aug 2023.

Key facts

This page summarizes Deepa Prasad's Form 4 filing for Design Therapeutics, Inc. (DSGN).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 30 Aug 2023, 18:06.

Change

Previous filing in this sequence was filed on 02 Jun 2023.
Current net transaction value: +$27,670.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

DSGN transaction

Common Stock

Purchase

Transaction value: $27,670
Shares: +12,000
Change %: +102%
Price: $2.31
Shares after: 23,806
Date: 29 Aug 2023
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.29 to $2.31, inclusive. The Reporting Person undertakes to provide the Issuer, and security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth herein.